Circulating microRNA-21 as Stable Blood-Based Markers for Patients With ISR After PCI
Keywords:In-stent restenosis, Percutaneous coronary interention, MiR-21, Intravascular ultrasound, Inflammation, proliferation, Ischemic heart disease
It recently has been reported that the in-stent restenosis (ISR) of expanded area after percutaneous coronary intervention (PCI) within six months can become a serious postoperative complication. A real-time quantitative PCR was used to analyze the expression of serum miR-21 in 33 ISR and 37 non-ISR patients after PCI. Expression of miR-21 was significantly higher in the ISR group compared with that in the NISR group, and a similar trend also occurred in factor- (TNF-α) level, Interleukin -6 (IL-6) level, and plaque area (PLA). However, a contrary trend occurred in the external elastic membrane area (EEM) and minimal lumen area (MLA). This study suggests that the increased expression of serum miR-21 is related to ISR after PCI, and miR-21 can be a new predictor of ISR.
Alraies MC, Darmoch F, Tummala R, Waksman R. 2017. Diagnosis and management challenges of in-stent restenosis in coronary arteries. World J Cardiol. 8:640–651.
Bentwich I, Avniel A, Karov Y, et al. 2005. Identification of hundreds of conserved and nonconserved human microRNAs, Nat Genet. 37,766-770.
Bonz AW, Lengenfelder B, Jacobs M, Strotmann J, Held S, Ertl G, Voelker W. 2003. Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. Am Heart J. 145:693–699.
Cai X, Hagedorn CH, Cullen BR. 2004. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs, RNA. 10, 1957- 1966.
Cao YY, Chen ZW, Gao YH, Wang XX, Ma JY, Chang SF, Qian JY, Ge JB. 2015. Exenatide Reduces Tumor Necrosis Factor-α-induced Apoptosis in Cardiomyocytes by Alleviating Mitochondrial Dysfunction. Chin Med J (Engl). 23: 3211–3218.
Casscells W, Roberts R, Towbin JA. 1994. Mechanisms of restenosis. Texas Heart Inst J. 21:68–77.
Chen ZW, Qian JY, Ma JY, Chang SF, Yun H, Jin H, et al. 2014. TNF-a-induced cardiomyocyte apoptosis contributes to cardiac dysfunction after coronary microembolization in mini-pigs. J Cell Mol Med. 18: 1953–1963.
Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, Fay WP, Simon DI, Edelman ER. 2003. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation. 108: 512–515.
Donners MM, Daemen MJ, Cleutjens KB, Heeneman S. 2003. Inflammation and restenosis: implications for therapy. Ann Med. 35:523–531.
Drachman DE, Simon DI. 2005. Inflammation as a mechanism and therapeutic target for in-stent restenosis. Curr Atheroscler Rep. 7:44–49.
Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Roxe T, Muller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S. 2010. Circulating microRNAs in patients with coronary artery disease. Circ Res. 107:677–684.
Fichtlscherer S, Zeiher AM, Dimmeler S. 2011. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol. 31:2383–2390.
Fujita S, Ito T, Mizutani T, et a1. 2008. MiR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. JMol Biol. 378, 492-504.
Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K, Fujikawa H, Shimada K. 2000. Interleukin 6 expression in coronary circulation after coronary angioplasty as risk factor for restenosis. Heart. 84:83–87.
Huang W, Tian SS, Hang PZ, Sun C, Guo J, Du ZM. 2016. Combination of microRNA-21 and microRNA-146a Attenuates Cardiac Dysfunction and Apoptosis During Acute Myocardial Infarction in Mice. Mol Ther Nucleic Acids. 3:e296.
Ikeda U, Ito T, Shimada K. 2001. Interleukin-6 and acute coronary syndrome. Clinic Cardiol. 24:701–704.
Jansen F, Schäfer L, Wang H, Schmitz T, Flender A, Schueler R, et al. 2017. Kinetics of Circulating MicroRNAs in Response to Cardiac Stress in Patients With Coronary Artery Disease. J Am Heart Assoc. 8:e005270.
Ji R, Cheng Y, Yue J, et a1. 2007. MicroRNA expression signature and antisense-mediated epletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res. 100, 1579-1588.
Kim MS, Dean LS. 2011. In-Stent Restenosis. Cardiovasc Ther. 29:190– 8.
Lagos-Quintana M, Rauhut R, Yalcin A, et a1. 2002. Identification of tissue specific micmRNAs from mouse, Curr Biol 12:735-739.
Li-Sha G, Peng C, Yue-Chun L. 2015. Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review. BMC Cardiovasc Disord. 15:101.
Liang H, Zhang C, Ban T, et a1. 2012. A novel reciprocal loop between microRNA-21 and TGFbetaRIII is involved in cardiac fibrosis. Int JBiochem Cell Bio. l44:2152- 2160.
Libby P, Simon DI, Rogers C. 2003. Inflammation and artery injury. In: Topol E, editor. Textbook of interventional cardiology. Philadelphia: Saunders. pp. 381–389.
Lindsey BD, Martin KH, Jiang X, Dayton PA. 2016. Adaptive windowing in contrast-enhanced intravascular ultrasound imaging. Ultrasonics. 70:123–135.
Ma N, Bai J, Zhang W, Luo H, Zhang X, Liu D, Qiao C. 2016. Trimetazidine protects against cardiac ischemia/reperfusion injury via effects on cardiacmiRNA-21 expression, Akt and the Bcl 2/Bax pathway. Mol Med Rep. 5:4216-4222.
Maehara A, Mintz GS, Weissman NJ. 2009. Advances in intravascular imaging. Circ Cardiovasc Interv. 2:482–490.
Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. 2001. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 37:1478–1492.
Mitchell PS, Parkin RK, Kroh EM, et a. 2008. Circulating microRNAs as stable blood-based markers for cancer detection, Proc Natl Acad Sci USA. 105:10513- 10518.
Pleva L, Kovarova P, Faldynova L, Plevova P, Hilscherova S, Zapletalova J, Kusnierova P, Kukla P. 2015. The rs1803274 polymorphism of the BCHE gene is associated with an increased risk of coronary in-stent restenosis. BMC Cardiovasc Disord. 15:135.
Qiang S, checked by Lang L. 2013. The research progress of relationship between microRNA-21 and ischemic heart disease. Chin Circ. 28,390-392.
Qin Y, Yu Y, Dong H, et a1. 2012. MicroRNA 21 inhibits left ventricular remodeling in the early phase of rat model with ischemia-reperfusion injury by suppressing cell apoptosis, Int J Med Sci. 9:413-423.
Räber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S, Moschovitis A, Vogel R, Kalesan B, Seiler C, Eberli F, Lüscher TF, Meier B, Jüni P, Windecker S. 2011. Fiveyear clinical and angiographic outcomes of a randomized comparison of sirolimuseluting and paclitaxeleluting stents: results of the SirolimusEluting Versus PaclitaxelEluting Stents for Coronary Revascularization LATE trial. Circulation 123:28192828.
Ren Y, Chen KJ, Ruan XM. 2008. [Systematic review of randomized controlled trials on preventing and treating restenosis after percutaneous coronary intervention with Chinese medicine]. [Article in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 28: 597–601.
Roy S, Khanna S, Hussain S-RA, Biswas S, Azad A, Rink C, Gnyawali S, Shilo S, Nuovo GJ, Sen CK. 2009. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res. 82:21–29.
Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King III SB, Loop FD, et al. 1988. Guidelines for percutaneous transluminal coronary angioplasty: A report of the American College of Cardiology/American Heart Association Task Force on the Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. Circulation. 2:486–502.
Sabatel C, Malvaux L, Bovy N. et a1. 2011. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. Plos One. 6:e16979.
Schillinger M, Minar E. 2005. Restenosis after percutaneous angioplasty: the role of vascular inflammation. Vasc Health Risk Manag. 1:73–78.
Schulz R, Aker S, Belosjorow S, Heusch G. 2004. TNFalpha in ischemia/reperfusion injury and heart failure. Basic Res Cardiol. 99: 8– 11.
Shen XH, Han YJ, Zhang DX, Cui XS, Kim NH. 2009. A link between the Interleukin-6/Stat3 anti-apoptotic pathway and microRNA-21 in preimplantation mouse embryos. Mol Reprod Dev. 76: 854–862.
Skyschally A, Gres P, Hoffmann S, Haude M, Erbel R, Schulz R, et al. 2007. Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: Progressive contractile dysfunction versus delayed protection against infarction. Circ Res. 100:140–146.
Small EM, Olson EN. 2011. Pervasive roles of microRNAs in cardiovascular biology. Nature. 469:336–342.
Song J, Hu B, Qu H, et a1. 2012. Mechanical stretch modulates microRNA 21 expression, participating in proliferation and apeptosis in cultured human aortic smooth muscle cells, Plos One. 7:e47657.
Szkodzinski J, Blazelonis A, Wilczek K, Hudzik B, Romanowski W, Gasior M, Wojnar R, Lekston A, Polonski L, Zubelewicz-Szkodzinska B. 2009. The role of interleukin-6 and transforming growth factor-β1 in predicting restenosis within stented infarct-related artery. Int J Immunopathol Pharmacol. 22: 493–500.
Wang XW, Zhang C, Lee KC, He XJ, Lu ZQ, Huang C. 2017. Adenovirus-Mediated Gene Transfer of microRNA-21 Sponge Inhibits Neointimal Hyperplasia in Rat Vein GraftsInt J Biol Sci. 10, 1309–1319.
Xu L, Xu Q, Li X, Zhang X. 2017. MicroRNA-21 regulates the proliferation and apoptosis of cervical cancer cells via tumor necrosis factor-α. Mol Med Rep. 4:4659– 4663.
Yang SJ, Zhang Y, Liu Y. 2015. Research on expression of miRNA-21 in the peripheral blood of coronary heart disease and its clinical significance. Zhong Guo Ying Yong Sheng Li Xue Za Zhi. 2:127- 31.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).